Ticlopidine

Ticlopidine
Clinical data
Trade namesTiclid
AHFS/Drugs.comMonograph
MedlinePlusa695036
License data
Pregnancy
category
  • AU: B1
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability>80%
Protein binding98%
MetabolismLiver
Elimination half-life12 hours (single dose)
4–5 days (repeated dosing)
ExcretionKidney and fecal
Identifiers
  • 5-(2-Chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.054.071 Edit this at Wikidata
Chemical and physical data
FormulaC14H14ClNS
Molar mass263.78 g·mol−1
3D model (JSmol)
  • Clc1ccccc1CN3Cc2c(scc2)CC3
  • InChI=1S/C14H14ClNS/c15-13-4-2-1-3-11(13)9-16-7-5-14-12(10-16)6-8-17-14/h1-4,6,8H,5,7,9-10H2 checkY
  • Key:PHWBOXQYWZNQIN-UHFFFAOYSA-N checkY
  (verify)

Ticlopidine, sold under the brand name Ticlid, is a medication used to reduce the risk of thrombotic strokes.[1] It is an antiplatelet drug in the thienopyridine family which is an adenosine diphosphate (ADP) receptor inhibitor. Research initially showed that it was useful for preventing strokes and coronary stent occlusions. However, because of its rare but serious side effects of neutropenia and thrombotic microangiopathy it was primarily used in patients in whom aspirin was not tolerated, or in whom dual antiplatelet therapy was desirable. With the advent of newer and safer antiplatelet drugs such as clopidogrel and ticagrelor, its use remained limited.

It was patented in 1973 and approved for medical use in 1978.[5]

  1. ^ a b "Ticlopidine hydrochloride tablet, film coated". DailyMed. Retrieved 29 August 2021.
  2. ^ "Ticlid (ticlopidine hydrochloride) tablets". DailyMed. Retrieved 29 August 2021.
  3. ^ "Drug Approval Package: Ticlid (Ticlopidine Hydrochloride) NDA #19-979/S-018". U.S. Food and Drug Administration (FDA). 24 December 1999. Retrieved 30 August 2021.
  4. ^ "Active substance: ticlopidine" (PDF). List of nationally authorised medicinal products. European Medicines Agency. 14 January 2021.
  5. ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 453. ISBN 9783527607495.